Recombinant soluble CD137 prevents type one diabetes in nonobese diabetic mice

Journal of Autoimmunity

Volumn 47, Issue , 2013, Pages 94-103

  Kachapati, Kritika ^a   Bednar, Kyle J ^a   Adams, David E ^a   Wu, Yuehong ^a   Mittler, Robert S ^b   Jordan, Michael B ^c   Hinerman, Jennifer M ^a   Herr, Andrew B ^a   Ridgway, William M ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Autoimmune diabetes; Immunoregulation; T cells

Indexed keywords

CD137 ANTIGEN; CD137 LIGAND; LENTIVIRUS VECTOR; RECOMBINANT ANTIGEN; RECOMBINANT SOLUBLE CD137 ANTIGEN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE LOCUS; GLUCOSE URINE LEVEL; HYPOTHESIS; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOGENICITY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RESTRICTION SITE; SEDIMENTATION RATE; T LYMPHOCYTE; VIRUS PARTICLE; WESTERN BLOTTING;

AUTOIMMUNE DIABETES; IMMUNOREGULATION; T CELLS;

4-1BB LIGAND; ANIMALS; ANTIGENS, CD137; AUTOIMMUNITY; CELL PROLIFERATION; DIABETES MELLITUS, TYPE 1; FEMALE; IMMUNE TOLERANCE; INSULIN; INSULIN-SECRETING CELLS; MICE; MICE, INBRED NOD; RECOMBINANT PROTEINS; T-LYMPHOCYTES, REGULATORY;

EID: 84888197665     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.09.002     Document Type: Article

References (46)

1. Wicker L.S., Todd J.A., Peterson L.B. Genetic control of autoimmune diabetes in the NOD mouse. Annu Rev Immunol 1995, 13:179-200.
2. Lyons P.A., Hancock W.W., Denny P., Lord C.J., Hill N.J., Armitage N., et al. The NOD Idd9 genetic interval influences the pathogenicity of insulitis and contains molecular variants of Cd30, Tnfr2, and Cd137. Immunity 2000, 13:107-115.
3. Cannons J.L., Chamberlain G., Howson J., Smink L.J., Todd J.A., Peterson L.B., et al. Genetic and functional association of the immune signaling molecule 4-1BB (CD137/TNFRSF9) with type 1 diabetes. J Autoimmun 2005, 25:13-20.
4. Irie J., Wu Y., Kachapati K., Mittler R.S., Ridgway W.M. Modulating protective and pathogenic CD4+ subsets via CD137 in type 1 diabetes. Diabetes 2007, 56:186-196.
5. Kachapati K., Adams D.E., Wu Y., Steward C.A., Rainbow D.B., Wicker L.S., et al. The B10 Idd9.3 locus mediates accumulation of functionally superior CD137(+) regulatory T cells in the nonobese diabetic type 1 diabetes model. J Immunol 2012, 189:5001-5015.
6. Croft M. Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine Growth Factor Rev 2003, 14:265-273.
7. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?. Nat Rev Immunol 2003, 3:609-620.
8. Vinay D.S., Cha K., Kwon B.S. Dual immunoregulatory pathways of 4-1BB signaling. J Mol Med 2006, 84:726-736.
9. Vinay D.S., Kwon B.S. Role of 4-1BB in immune responses. Semin Immunol 1998, 10:481-489.
10. Lee H.W., Park S.J., Choi B.K., Kim H.H., Nam K.O., Kwon B.S. 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol 2002, 169:4882-4888.
11. Starck L., Scholz C., Dorken B., Daniel P.T. Costimulation by CD137/4-1BB inhibits T cell apoptosis and induces Bcl-xL and c-FLIP(short) via phosphatidylinositol 3-kinase and AKT/protein kinase B. Eur J Immunol 2005, 35:1257-1266.
12. Zheng G., Wang B., Chen A. The 4-1BB costimulation augments the proliferation of CD4+CD25+ regulatory T cells. J Immunol 2004, 173:2428-2434.
13. Elpek K.G., Yolcu E.S., Franke D.D., Lacelle C., Schabowsky R.H., Shirwan H. Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling. J Immunol 2007, 179:7295-7304.
14. Setareh M., Schwarz H., Lotz M. A mRNA variant encoding a soluble form of 4-1BB, a member of the murine NGF/TNF receptor family. Gene 1995, 164:311-315.
15. Hurtado J.C., Kim S.H., Pollok K.E., Lee Z.H., Kwon B.S. Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28. J Immunol 1995, 155:3360-3367.
16. Michel J., Schwarz H. Expression of soluble CD137 correlates with activation-induced cell death of lymphocytes. Cytokine 2000, 12:742-746.
17. Jung H.W., Choi S.W., Choi J.I., Kwon B.S. Serum concentrations of soluble 4-1BB and 4-1BB ligand correlated with the disease severity in rheumatoid arthritis. Exp Mol Med 2004, 36:13-22.
18. Liu G.Z., Gomes A.C., Putheti P., Karrenbauer V., Kostulas K., Press R., et al. Increased soluble 4-1BB ligand (4-1BBL) levels in peripheral blood of patients with multiple sclerosis. Scand J Immunol 2006, 64:412-419.
19. Sharief M.K. Heightened intrathecal release of soluble CD137 in patients with multiple sclerosis. Eur J Neurol 2002, 9:49-54.
20. Kachapati K., Adams D., Bednar K., Ridgway W.M. The Non-Obese Diabetic (NOD) Mouse as a Model of Human Type 1 Diabetes. Methods Mol Biol 2012, 933:3-16.
21. Shuford W.W., Klussman K., Tritchler D.D., Loo D.T., Chalupny J., Siadak A.W., et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997, 186:47-55.
22. Stoeckel K., Gagnon C., Guroff G., Thoenen H. Purification of nerve growth factor antibodies by affinity chromatography. J Neurochem 1976, 26:1207-1211.
23. Durkee K.H., Roh B.H., Doellgast G.J. Immunoaffinity chromatographic purification of Russell's viper venom factor X activator using elution in high concentrations of magnesium chloride. Protein Expr Purif 1993, 4:405-411.
24. Arch R.H., Gedrich R.W., Thompson C.B. Translocation of TRAF proteins regulates apoptotic threshold of cells. Biochem Biophys Res Commun 2000, 272:936-945.
25. Schuck P. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. Biophys J 2000, 78:1606-1619.
26. Melanitou E., Joly F., Lathrop M., Boitard C., Avner P. Evidence for the presence of insulin-dependent diabetes-associated alleles on the distal part of mouse chromosome 6. Genome Res 1998, 8:608-620.
27. Jimeno R., Gomariz R.P., Gutierrez-Canas I., Martinez C., Juarranz Y., Leceta J. New insights into the role of VIP on the ratio of T-cell subsets during the development of autoimmune diabetes. Immunol Cell Biol 2010, 88:734-745.
28. Weber K., Bartsch U., Stocking C., Fehse B. A multicolor panel of novel lentiviral "gene ontology" (LeGO) vectors for functional gene analysis. Mol Ther 2008, 16:698-706.
29. Weber K., Mock U., Petrowitz B., Bartsch U., Fehse B. Lentiviral gene ontology (LeGO) vectors equipped with novel drug-selectable fluorescent proteins: new building blocks for cell marking and multi-gene analysis. Gene Ther 2010, 17:511-520.
30. Matsushima Y., Makino H., Kanatsuka A., Osegawa M., Kumagai A., Nishimura M., et al. Pancreatic somatostatin contents in spontaneously diabetic KK and non-obese diabetic (NOD) mice. Horm Metab Res 1982, 14:292-298.
31. Tasaka Y., Inoue Y., Marumo K., Mizuno Y., Hirata Y., Akao Y. Insulin, glucagon and somatostatin content of the non-obese diabetic (NOD) mouse pancreas and plasma virus antibodies to Coxsackie B- and reoviruses. Tohoku J Exp Med 1985, 146:153-162.
32. Atkinson M.A., Maclaren N.K., Luchetta R. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 1990, 39:933-937.
33. Jacob C.O., Aiso S., Michie S.A., McDevitt H.O., Acha-Orbea H. Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-alpha and interleukin 1. Proc Natl Acad Sci U S A 1990, 87:968-972.
34. Chen Z., Herman A.E., Matos M., Mathis D., Benoist C. Where CD4+CD25+ T reg cells impinge on autoimmune diabetes. J Exp Med 2005, 202:1387-1397.
35. Pakala S.V., Chivetta M., Kelly C.B., Katz J.D. In autoimmune diabetes the transition from benign to pernicious insulitis requires an islet cell response to tumor necrosis factor alpha. J Exp Med 1999, 189:1053-1062.
36. Poirot L., Benoist C., Mathis D. Natural killer cells distinguish innocuous and destructive forms of pancreatic islet autoimmunity. Proc Natl Acad Sci U S A 2004, 101:8102-8107.
37. Shao Z., Sun F., Koh D.R., Schwarz H. Characterisation of soluble murine CD137 and its association with systemic lupus. Mol Immunol 2008, 45:3990-3999.
38. Kwon B.S., Kozak C.A., Kim K.K., Pickard R.T. Genomic organization and chromosomal localization of the T-cell antigen 4-1BB. J Immunol 1994, 152:2256-2262.
39. Chan F.K. Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling. Cytokine 2007, 37:101-107.
40. Foell J.L., Diez-Mendiondo B.I., Diez O.H., Holzer U., Ruck P., Bapat A.S., et al. Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance. Immunology 2004, 113:89-98.
41. Foell J., McCausland M., Burch J., Corriazzi N., Yan X.J., Suwyn C., et al. CD137-mediated T cell co-stimulation terminates existing autoimmune disease in SLE-prone NZB/NZW F1 mice. Ann N Y Acad Sci 2003, 987:230-235.
42. Langstein J., Michel J., Fritsche J., Kreutz M., Andreesen R., Schwarz H. CD137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte activation via bidirectional signaling. J Immunol 1998, 160:2488-2494.
43. Kim D.K., Lee S.C., Lee H.W. CD137 ligand-mediated reverse signals increase cell viability and cytokine expression in murine myeloid cells: involvement of mTOR/p70S6 kinase and Akt. Eur J Immunol 2009, 39:2617-2628.
44. Pauly S., Broll K., Wittmann M., Giegerich G., Schwarz H. CD137 is expressed by follicular dendritic cells and costimulates B lymphocyte activation in germinal centers. J Leukoc Biol 2002, 72:35-42.
45. Rabu C., Quemener A., Jacques Y., Echasserieau K., Vusio P., Lang F. Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity. J Biol Chem 2005, 280:41472-41481.
46. Lynch D.H. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol Rev 2008, 222:277-286.